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The authors reply:
W
e thank Long et al (1) for their comment on our 
meta-analysis of randomized controlled trials 
(RCTs) on vitamin C supplementation in critically 
ill patients (2), recently published in Critical Care Medicine. 
We performed several analyses to evaluate any possible sub-
group effects (e.g., different settings, route of administration, 
vitamin C only, high-dose IV vitamin C). We concluded that 
“the quality and quantity of evidence is still insufficient to 
draw firm conclusions, not supporting neither discouraging 
the systematic administration of vitamin C in these popula-
tions” (2).
Our subgroup analysis on RCTs performed in ICU patients 
receiving IV vitamin C with a dose higher than 5,000 mg/d 
(Fig. 4 in [2]) showed no significant reduction in mortality 
in this high-dose regimen (risk ratio, 0.83; 95% CI, 0.44–1.56; 
p = 0.57) even if the subanalysis was clearly unpowered since 
it included four trials and 289 patients, and further limited by 
clinical heterogeneity (subsetting, daily dose, year of publica-
tion). The results of secondary outcomes were inconclusive 
too (2).
As suggested by Long et al (1), we have now performed a 
subgroup analysis on mortality in ICU patients receiving IV 
vitamin C with a dose higher than 2,000 mg/d (six trials and 
513 patients) and the results are similar (risk ratio, 0.89; 95% 
CI, 0.59–1.34; p = 0.56) (Fig. 1).
The pharmacological and pathophysiological rationale be-
hind vitamin C administration in critically ill patients is strong 
and even a stronger rationale supports a high-dose IV reg-
imen. This interesting rationale is nicely summarized by Long 
et al (1), but actually not supported by strong randomized 
evidence. On the other hand, several small RCTs supported the 
use of “lower dose” vitamin C regimen in a different setting 
(cardiac surgery). This made also low dose supplementation an 
interesting regimen to assess in a systematic review.
We fully agree with Long et al (1) that pharmacokinetics 
properties, together with pharmacodynamics and pathophys-
iological characteristics, must be taken into considerations 
when performing clinical trials. However, we should also take 
into consideration that some idea based on pathophysiology 
and pharmacology could be inconclusive or even detrimental. 
There are several examples in the field of critical care medi-
cine: activated protein C in sepsis (3), levosimendan in sepsis 
(4), early parenteral nutrition in critically ill patients (5), poly-
myxin B hemoperfusion in sepsis (6), glutamine in critically ill 
patients (7), corticosteroids or 4% albumin in traumatic brain 
injury (8), aprotinin in cardiac surgery (8), and so on.
In conclusion, we found that the quality and quantity of 
randomized evidence is still insufficient to draw firm conclu-
sions on effect of vitamin C on clinically relevant outcomes. In 
cardiac surgery, beneficial effects on postoperative atrial fibril-
lation and ICU or hospital length of stay are unclear. In ICU 
patients, aggregated randomized evidence does not support 
neither discourage the administration of vitamin C in order 
to reduce mortality. High-dose IV vitamin C is a fascinating 
option that merits further investigation.
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Figure 1. Forest plot for mortality at longest follow-up available in ICU patients randomized to receive high-dose IV vitamin C. df = degrees of freedom, 
M-H = Mantel-Haenszel.
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